以数据为导向的HbA1c/HDL-C比率与冠状动脉化之间的关系分析:横截面研究
Chen Chen1, Mingkang Li2,3, Gaoliang Yan2,3
1School of Cyber Science and Engineering, Southeast University, Nanjing, Jiangsu, China.
Scientific reports
|August 29, 2025
概括
糖化血红蛋白A1c (HbA1c) / 高密度脂蛋白胆固醇 (HDL- C) 的比率与成人冠状动脉化 (CAC) 有关. 升高的HbA1c/HDL-C比率可以独立预测CAC,这表明其在心血管风险评估中的有用性.
科学领域:
- 心血管疾病研究
- 代谢综合征研究
- 生物标志物发现
背景情况:
- 冠状动脉化 (CAC) 是心血管疾病发展的关键标志物.
- 不调节的葡萄糖和脂质代谢与CAC病变密切相关.
- 对于预防策略来说,确定CAC风险的新生物标志物至关重要.
研究的目的:
- 调查糖化血红蛋白A1c (HbA1c) 与高密度脂蛋白胆固醇 (HDL-C) 的比率与CAC之间的关系.
- 确定HbA1c/HDL-C比率是否是无症状成年人中CAC的独立预测指标.
- 开发和评估一个包含HbA1c/HDL-C比率的CAC预测模型和名图.
主要方法:
- 一项涉及1608名符合条件的参与者的横截面研究.
- 计算HbA1c/HDL-C的比率
- 包括LASSO回归,物流回归和ROC曲线分析在内的统计分析.
- 开发和验证一个预测名录.
主要成果:
- 与对照组相比,CAC组的HbA1c/ HDL- C比率明显高 (p < 0. 001).
- 较高的HbA1c/ HDL- C比率 (≥4. 99) 与较高的CAC患病率相关 (30. 04%对比17. 83%,p < 0. 001).
- HbA1c/ HDL- C比率成为CAC的一个独立风险因素 (OR,1. 135;95% CI,1. 008-1. 279; p = 0. 037).
- 结合HbA1c/HDL-C比率的预测模型实现了0. 718的AUC.
结论:
- HbA1c/HDL-C比率与CAC的存在有显著的相关性.
- 这一比率可以作为无症状的未患有心血管疾病的成年人中CAC的独立预测指标.
- 开发的诺米图显示了对CAC风险评估的良好临床效用.
更多相关视频
06:57Author Spotlight: Advancing Cardiovascular Imaging - Introducing the Spatially Weighted Calcium Score for Early Disease Detection
Published on: September 22, 2023
1.1K
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
523
相关概念视频
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
119
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
119
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:26Coronary Artery Disease II: Pathophysiology
33
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
33
01:12Hazard Ratio
241
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
241
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33